西洛他唑片对急性冠脉综合征经皮冠状动脉介入术后患者内皮功能的影响  

Effect of cilostazol on endothelial function in patients with acute coronary syndrome after percutaneous corazonary intervention

作　　者：艾秋玲 左雪容 杨静 徐琼 于颖 AI Qiu-ling;ZUO Xue-rong;YANG Jing;XU Qiong;YU Ying(Department of Cardiovascular Diseases,Enshi Zhou Nationalities Hospital,Enshi 445000,Hubei Province,China)

机构地区：[1]恩施州民族医院心血管病科,湖北恩施445000

出　　处：《中国临床药理学杂志》2020年第17期2610-2613,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的探讨西洛他唑片对急性冠脉综合征(ACS)经皮冠状动脉介入(PCI)术后患者内皮功能的影响。方法将188例在我院确诊并成功接受PCI术治疗的额入ACS患者随机分为试验组(n=98)和对照组(n=90)。对照组患者PCI术后给予阿司匹林肠溶片100 mg,硫酸氢氯吡格雷片75 mg,每日1次。试验组患者则在对照组的基础上给予西洛他唑片100 mg,每日2次。2组患者均连续治疗1个月。比较2组患者血管内皮功能及主要不良心血管事件(MACE)、药物不良反应发生情况。结果治疗后,试验组和对照组脂联素(APN)分别为(4.95±0.89),(3.12±0.74)ng·L^-1,内皮素-1(ET-1)分别为(42.31±18.47),(56.44±20.12)ng·L^-1,一氧化氮(NO)分别为(68.56±23.17),(49.18±18.95)μmoL·L^-1,肱动脉内皮依赖血流介导的血管扩张率(FMD)分别为(6.20±1.79),(4.93±1.40)%,差异均有统计学意义(均P<0.05)。随访期间,试验组和对照组MACE发生率分别为7.12%(7例/98例)和17.78%(16例/90例),差异有统计学意义(P<0.05)。结论ACS PCI术后使用西洛他唑片可改善患者血管内皮功能,有效降低MACE发生率,安全性较高。Objective To investigate the effect of cilostazol on endothelial function in patients with acute coronary syndrome(ACS)after percutaneous corazonary intervention(PCI).Methods A total of 188 patients with ACS and successfully treated with PCI in our hospital were randomly divided into the treatment group(n=98)and control group(n=90).After PCI,control group were given Aspirin enteric-coated tablets 100 mg,Clopidogrel hydrogen sulfate tablets 75 mg,once daily,and treatment group were given cilostazol 100 mg,twice daily on the basis of control group.The vascular endothelial function and incidence of major adverse cardiovascular events(MACE),adverse reactions were compared between the two groups.Results After treatment,the adiponectin(APN)in treatment group and control group were(4.95±0.89),(3.12±0.74)ng·L^-1,endothelin-1(ET-1)were(42.31±18.47),(56.44±20.12)ng·L^-1,nitric oxide(NO)were(68.56±23.17),(49.18±18.95)μmoL·L^-1,the flow-mediated diameter(FMD)were(6.20±1.79)%,(4.93±1.40)%respectively,all with significant differences(all P<0.05).During the follow-up period,the incidences of MACE in treatment group and control group were 7.12%(7 cases/98 cases)and 17.78%(16 cases/90 cases),with significant differences(P<0.05).Conclusion Cilostazol can significantly improve the vascular endothelial function in the patients with ACS after PCI,effectively reduces the incidence of MACE with high safety.

关 键 词：急性冠脉综合征 经皮冠状动脉介入术 西洛他唑片 内皮功能 

分 类 号：R97[医药卫生—药品]